{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-165170","form_type":"8-K","ticker":"IMA","cik":"0001835579","company_name":"ImageneBio, Inc.","filed_at":"2025-07-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.227000+00:00","generated_at":"2026-05-18T01:23:11.062088+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Ikena Oncology completes merger with Inmagene, becomes ImageneBio, raises $75M private placement","bullets":["Merger closed July 25, 2025; combined company renamed ImageneBio, Inc., trading on Nasdaq under IMA starting July 28.","Concurrent $75.0M private placement from investors including Deep Track Capital, Foresite Capital, RTW Investments, and existing Ikena investors.","Legacy Inmagene holders own ~55% (pre-financing) or ~43.1% (post-financing); Ikena holders own ~45% (pre) or ~35.3% (post); new investors own ~21.6%.","ImageneBio to advance IMG-007 Phase 2b trial in moderate-to-severe atopic dermatitis; topline readout expected Q4 2026.","Kristin Yarema, Ph.D. appointed CEO; Ikena implemented a 1-for-12 reverse stock split prior to closing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-165170","json":"https://secwatch.observer/filing/0001193125-25-165170.json","markdown":"https://secwatch.observer/filing/0001193125-25-165170.md","text":"https://secwatch.observer/filing/0001193125-25-165170.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835579/000119312525165170/0001193125-25-165170-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835579/000119312525165170/d62567d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-18T01:23:11.062088+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}